HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE
The effects of haloperidol in the management of elderly patients with chronic brain syndrome with cerebral arteriosclerosis or senile brain disease were investigated in an initial open phase (6 patients) and a subsequent randomized double-blind placebo-controlled phase (18 patients). Haloperidol app...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1964-06, Vol.120 (12), p.1190-1192 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1192 |
|---|---|
| container_issue | 12 |
| container_start_page | 1190 |
| container_title | The American journal of psychiatry |
| container_volume | 120 |
| creator | SUGERMAN, A. ARTHUR WILLIAMS, BENJAMIN H ADLERSTEIN, ARTHUR M |
| description | The effects of haloperidol in the management of elderly patients with chronic brain syndrome with cerebral arteriosclerosis or senile brain disease were investigated in an initial open phase (6 patients) and a subsequent randomized double-blind placebo-controlled phase (18 patients). Haloperidol appears to be an effective compound in patients who are agitated, overactive and hostile. Side effects include sedation and extrapyramidal symptoms. The dose level should be considerably lower than that generally used in schizophrenic patients and should probably not exceed 4 mg. daily. Maintenance doses of about 1 mg. daily appear adequate in most cases. Hypotension was not a complication and no untoward effects on liver function or bone marrow were noted. |
| doi_str_mv | 10.1176/ajp.120.12.1190 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1310602036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1310602036</sourcerecordid><originalsourceid>FETCH-LOGICAL-a358t-a17c3c461de240bceef29f254ec00f35e7ed7d0b1f707cb91ccb62adbc192ba93</originalsourceid><addsrcrecordid>eNp1kEFLw0AQRhdRbK2evUnAq2lndrPZ5hiStAkEU9IKelo2mw20WBuT9tB_75YW9OJhGD548w08Qh4RxojCn6hNO0ZqA7U5gCsyRM64KyidXpMhAFA34Ox9QO76fmMjMEFvyQA95J7gfEhYGubFIimzuMid7NVZpYmzWH5EaRauyixy4mxZlHFSLp1i5hR57ITz5J7cNOqzNw-XPSJvs2QVpW5ezLMozF3F-HTvKhSaac_H2lAPKm1MQ4OGcs9ogIZxI0wtaqiwESB0FaDWlU9VXWkMaKUCNiLP5962230fTL-Xm92h-7IvJTIEHygw31KTM6W7Xd93ppFtt96q7igR5EmStJKklWRHniTZi6dL76HamvqXv1ixwMsZUG27_vP0n74f5_ZqyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310602036</pqid></control><display><type>article</type><title>HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>SUGERMAN, A. ARTHUR ; WILLIAMS, BENJAMIN H ; ADLERSTEIN, ARTHUR M</creator><creatorcontrib>SUGERMAN, A. ARTHUR ; WILLIAMS, BENJAMIN H ; ADLERSTEIN, ARTHUR M</creatorcontrib><description>The effects of haloperidol in the management of elderly patients with chronic brain syndrome with cerebral arteriosclerosis or senile brain disease were investigated in an initial open phase (6 patients) and a subsequent randomized double-blind placebo-controlled phase (18 patients). Haloperidol appears to be an effective compound in patients who are agitated, overactive and hostile. Side effects include sedation and extrapyramidal symptoms. The dose level should be considerably lower than that generally used in schizophrenic patients and should probably not exceed 4 mg. daily. Maintenance doses of about 1 mg. daily appear adequate in most cases. Hypotension was not a complication and no untoward effects on liver function or bone marrow were noted.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.120.12.1190</identifier><identifier>PMID: 14154755</identifier><language>eng</language><publisher>United States: American Psychiatric Publishing</publisher><subject>Biomedical Research ; Dementia ; Geriatrics ; Haloperidol ; Intracranial Arteriosclerosis ; Mental Disorders ; Placebos ; Psychotic Disorders ; Toxicology</subject><ispartof>The American journal of psychiatry, 1964-06, Vol.120 (12), p.1190-1192</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a358t-a17c3c461de240bceef29f254ec00f35e7ed7d0b1f707cb91ccb62adbc192ba93</citedby><cites>FETCH-LOGICAL-a358t-a17c3c461de240bceef29f254ec00f35e7ed7d0b1f707cb91ccb62adbc192ba93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.120.12.1190$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.120.12.1190$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,777,781,2846,21610,27850,27905,27906,77540,77541</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14154755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SUGERMAN, A. ARTHUR</creatorcontrib><creatorcontrib>WILLIAMS, BENJAMIN H</creatorcontrib><creatorcontrib>ADLERSTEIN, ARTHUR M</creatorcontrib><title>HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>The effects of haloperidol in the management of elderly patients with chronic brain syndrome with cerebral arteriosclerosis or senile brain disease were investigated in an initial open phase (6 patients) and a subsequent randomized double-blind placebo-controlled phase (18 patients). Haloperidol appears to be an effective compound in patients who are agitated, overactive and hostile. Side effects include sedation and extrapyramidal symptoms. The dose level should be considerably lower than that generally used in schizophrenic patients and should probably not exceed 4 mg. daily. Maintenance doses of about 1 mg. daily appear adequate in most cases. Hypotension was not a complication and no untoward effects on liver function or bone marrow were noted.</description><subject>Biomedical Research</subject><subject>Dementia</subject><subject>Geriatrics</subject><subject>Haloperidol</subject><subject>Intracranial Arteriosclerosis</subject><subject>Mental Disorders</subject><subject>Placebos</subject><subject>Psychotic Disorders</subject><subject>Toxicology</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1964</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp1kEFLw0AQRhdRbK2evUnAq2lndrPZ5hiStAkEU9IKelo2mw20WBuT9tB_75YW9OJhGD548w08Qh4RxojCn6hNO0ZqA7U5gCsyRM64KyidXpMhAFA34Ox9QO76fmMjMEFvyQA95J7gfEhYGubFIimzuMid7NVZpYmzWH5EaRauyixy4mxZlHFSLp1i5hR57ITz5J7cNOqzNw-XPSJvs2QVpW5ezLMozF3F-HTvKhSaac_H2lAPKm1MQ4OGcs9ogIZxI0wtaqiwESB0FaDWlU9VXWkMaKUCNiLP5962230fTL-Xm92h-7IvJTIEHygw31KTM6W7Xd93ppFtt96q7igR5EmStJKklWRHniTZi6dL76HamvqXv1ixwMsZUG27_vP0n74f5_ZqyQ</recordid><startdate>196406</startdate><enddate>196406</enddate><creator>SUGERMAN, A. ARTHUR</creator><creator>WILLIAMS, BENJAMIN H</creator><creator>ADLERSTEIN, ARTHUR M</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope></search><sort><creationdate>196406</creationdate><title>HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE</title><author>SUGERMAN, A. ARTHUR ; WILLIAMS, BENJAMIN H ; ADLERSTEIN, ARTHUR M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a358t-a17c3c461de240bceef29f254ec00f35e7ed7d0b1f707cb91ccb62adbc192ba93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1964</creationdate><topic>Biomedical Research</topic><topic>Dementia</topic><topic>Geriatrics</topic><topic>Haloperidol</topic><topic>Intracranial Arteriosclerosis</topic><topic>Mental Disorders</topic><topic>Placebos</topic><topic>Psychotic Disorders</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUGERMAN, A. ARTHUR</creatorcontrib><creatorcontrib>WILLIAMS, BENJAMIN H</creatorcontrib><creatorcontrib>ADLERSTEIN, ARTHUR M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUGERMAN, A. ARTHUR</au><au>WILLIAMS, BENJAMIN H</au><au>ADLERSTEIN, ARTHUR M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1964-06</date><risdate>1964</risdate><volume>120</volume><issue>12</issue><spage>1190</spage><epage>1192</epage><pages>1190-1192</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><abstract>The effects of haloperidol in the management of elderly patients with chronic brain syndrome with cerebral arteriosclerosis or senile brain disease were investigated in an initial open phase (6 patients) and a subsequent randomized double-blind placebo-controlled phase (18 patients). Haloperidol appears to be an effective compound in patients who are agitated, overactive and hostile. Side effects include sedation and extrapyramidal symptoms. The dose level should be considerably lower than that generally used in schizophrenic patients and should probably not exceed 4 mg. daily. Maintenance doses of about 1 mg. daily appear adequate in most cases. Hypotension was not a complication and no untoward effects on liver function or bone marrow were noted.</abstract><cop>United States</cop><pub>American Psychiatric Publishing</pub><pmid>14154755</pmid><doi>10.1176/ajp.120.12.1190</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1964-06, Vol.120 (12), p.1190-1192 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_journals_1310602036 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
| subjects | Biomedical Research Dementia Geriatrics Haloperidol Intracranial Arteriosclerosis Mental Disorders Placebos Psychotic Disorders Toxicology |
| title | HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A08%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HALOPERIDOL%20IN%20THE%20PSYCHIATRIC%20DISORDERS%20OF%20OLD%20AGE&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=SUGERMAN,%20A.%20ARTHUR&rft.date=1964-06&rft.volume=120&rft.issue=12&rft.spage=1190&rft.epage=1192&rft.pages=1190-1192&rft.issn=0002-953X&rft.eissn=1535-7228&rft_id=info:doi/10.1176/ajp.120.12.1190&rft_dat=%3Cproquest_cross%3E1310602036%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310602036&rft_id=info:pmid/14154755&rfr_iscdi=true |